However, recently published results of two large-scale phase-III de-escalation trials were rather disappointing: The RTOG-1016 trial included 805 p16+ oropharyngeal cancer patients and compared two treatment strategies in a non-inferiority approach: radiotherapy plus cetuximab vs. radiotherapy plus cisplatin [31]. Here, CDKN2A is linked to oropharynx cancer.